We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Wuhan General Group Inc (CE) | USOTC:WUHN | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 00:00:00 |
Wuhan Announces Appointment of Chief Medical Officer
Toronto, On -- September 18, 2018 -- InvestorsHub NewsWire -- Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the "Company"), today announced that it has appointed Leralta MoreraDr. Anna , ("Dr. Anna") as the company's chief medical officer (CMO), effective immediately. In her role as CMO, Dr. Anna will seek out and evaluate opportunities in the medical cannabis and cannabidiol (CBD) sectors.
Dr. Anna has established herself as a dedicated researcher, thought leader and medical practitioner in the medical cannabis field. She is relentless in advancing the medical community's understanding of cannabis and cannabinoids and ultimately in being able to provide society with alternative options to what are now standard practices. Her research to date has focused on the safety, efficacy, and effectiveness of cannabis and cannabinoids in pain and symptom management.
"I'm delighted to be bringing Dr. Anna into a senior position within Wuhan. The medical cannabis and CBD space are very lucrative - and for good reason. Anna's expertise in Integrative Medicine (IM) and strong leadership skills will be a tremendous asset to Wuhan as the company seeks to enter the CBD and other related verticals in the very near term.'' said Wuhan chief executive officer (CEO), Ramy Kamaneh.
Dr. Anna stated, "Not a day goes by where I don't come across an article, publication or scientific paper that mentions a potential new medical use for CBD. There's a huge market demand and an opportunity to profit from. What the industry needs is science-based solutions, and we have the team and the tools to satisfy this demand. I'm extremely excited to embark on this project with Wuhan."
Kamaneh added, "Wuhan recently announced a spin-off of the Company's Canadian tech-related business. It was an obvious next step for Wuhan to explore potential investment opportunities with big upside. The medical cannabis space is one we were very eager to take part in."
About Wuhan General Group (china) Inc
Wuhan General Group (China), Inc. is a Nevada investment company focus in the space of Cryptocurrency mining operations, industrial manufacturing of battery and electric Material handling equipment as well as in the application of artificial intelligence technologies to the mining, agriculture and construction industries. In addition, Wuhan is seeking out and evaluating opportunities in the medical cannabis and cannabidiol (CBD) sectors.
Wuhan General Group (China), Inc.
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
For further information contact:
Public Relations
E-mail: info@wuhn.org
Forward-Looking Statements
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
Source: Wuhan General Group (China), Inc
1 Year Wuhan General (CE) Chart |
1 Month Wuhan General (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions